Clinical Data for X4P-001-IO in Combination with Inlyta® (Axitinib) Demonstrated Encouraging Overall Response Rates (including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma

X4 Pharmaceuticals, a clinical stage biotechnology company developing a novel CXCR4 inhibitor to improve immune cell trafficking to treat cancer and rare diseases, today announced updated results from the Phase 1 part of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).

This entry was posted in Recent Development News: Q4 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »